Seattle Genetics Deserves Its Stock Rally

Seattle Genetics Stock Rallied
Seattle Genetics (SGEN) financial results started with Clay Siegall, Ph.D., President and Chief Executive Officer of the firm stating the following:

  • Seattle Genetics achieved record net sales in the U.S. and Canada for Adcetris, reflecting growth in frontline CD30-expressing peripheral T-cell lymphomas as well as frontline advanced Hodgkin lymphoma.  
  • The Biologics . . .
    This content is for paid subscribers.
    Please click here to subscribe or here to log in.